Discussion
4-Aminopyridine is used clinically for treatment of LamberEaton myasthenic syndrome and multiple sclerosis because by blocking potassium channel it prolongs action potentials thereby increasing transmitter release at the neuromuscular junction [1] . As an extension of our systematic study of the hydrogen bonding patterns of 4-aminopyridine with carboxylic acid, the title compound has been synthesized and the crystal structure determined. The asymmetric unit of the title crystal structure contains of one molecule of 4-aminopyridine cation, one molecule of 2-(pyridine-4-ylcarbamoyl)benzoate anion and one water molecule. Aproton transfer from the carboxyl group of 2-(pyridine-4-ylcarbamoyl)benzoic acid to atom N3 of 4-aminopyridine resulted in the formation of salt. This protonation leads to the widening of C16-N3-C17 angle of the pyridine ring to 120.8(2)°, compared to 115.3(1)°in the unprotonated 4-aminopyridine [2] . This type of protonation is observed in various 4-aminopyridine acid complexes [3, 4] . Other bond lengths and bond angles in 4-aminopyridinium are comparable to the values reported earlier for 4-aminopyridine [5] . The crystal packing is consolidated by intermolecular O-H···Oand N-H···Ohydrogen bonds. The molecules are further interlinked by the C-H···Onon-classical hydrogen bonds and p-p stacking into the 3D supramolecular architecture. 
